Therapy of acute myeloid leukemia: therapeutic targeting of tyrosine kinases

Joseph Cioccio, David Claxton

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Introduction: Tyrosine kinases (TKs) drive cell survival and proliferation in many normal and malignant cell types. TKs are frequently mutated in acute myeloid leukemia (AML) and hence are increasingly targeted. The management of AML has dramatically improved because of TKI-targeted treatment. Areas Covered: This review provides a biological background for TK inhibitors (TKIs) in AML and reviews their use in the clinic. TK expression and mutation in AML are explored with a focus on TKs associated with specific AML subsets and treatment outcomes. TKIs that specifically target FLT3, c-Kit, and Jak2 are discussed. TKI targeting of specific genes mutated in individual cases and general ‘untargeted’ use of these agents are highlighted. Lastly, the mechanisms TKI drug resistance in AML are explored. Expert Opinion: The use of TKIs in the clinic is improving outcomes for many patients. An improved understanding of tyrosine kinase biology and the expanding use of TKIs are likely to dramatically improve outcomes in the coming decade. TKIs and other targeted agents could gradually supplant the use of cytotoxic chemotherapy for AML.

Original languageEnglish (US)
Pages (from-to)337-349
Number of pages13
JournalExpert Opinion on Investigational Drugs
Volume28
Issue number4
DOIs
StatePublished - Apr 3 2019

Fingerprint

Acute Myeloid Leukemia
Protein-Tyrosine Kinases
Therapeutics
Gene Targeting
Expert Testimony
Drug Resistance
Cell Survival
Cell Proliferation
Drug Therapy
Mutation

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{fb25cd7e941a4ca49bc164b3ccab906a,
title = "Therapy of acute myeloid leukemia: therapeutic targeting of tyrosine kinases",
abstract = "Introduction: Tyrosine kinases (TKs) drive cell survival and proliferation in many normal and malignant cell types. TKs are frequently mutated in acute myeloid leukemia (AML) and hence are increasingly targeted. The management of AML has dramatically improved because of TKI-targeted treatment. Areas Covered: This review provides a biological background for TK inhibitors (TKIs) in AML and reviews their use in the clinic. TK expression and mutation in AML are explored with a focus on TKs associated with specific AML subsets and treatment outcomes. TKIs that specifically target FLT3, c-Kit, and Jak2 are discussed. TKI targeting of specific genes mutated in individual cases and general ‘untargeted’ use of these agents are highlighted. Lastly, the mechanisms TKI drug resistance in AML are explored. Expert Opinion: The use of TKIs in the clinic is improving outcomes for many patients. An improved understanding of tyrosine kinase biology and the expanding use of TKIs are likely to dramatically improve outcomes in the coming decade. TKIs and other targeted agents could gradually supplant the use of cytotoxic chemotherapy for AML.",
author = "Joseph Cioccio and David Claxton",
year = "2019",
month = "4",
day = "3",
doi = "10.1080/13543784.2019.1584610",
language = "English (US)",
volume = "28",
pages = "337--349",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Taylor and Francis Ltd.",
number = "4",

}

Therapy of acute myeloid leukemia : therapeutic targeting of tyrosine kinases. / Cioccio, Joseph; Claxton, David.

In: Expert Opinion on Investigational Drugs, Vol. 28, No. 4, 03.04.2019, p. 337-349.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Therapy of acute myeloid leukemia

T2 - therapeutic targeting of tyrosine kinases

AU - Cioccio, Joseph

AU - Claxton, David

PY - 2019/4/3

Y1 - 2019/4/3

N2 - Introduction: Tyrosine kinases (TKs) drive cell survival and proliferation in many normal and malignant cell types. TKs are frequently mutated in acute myeloid leukemia (AML) and hence are increasingly targeted. The management of AML has dramatically improved because of TKI-targeted treatment. Areas Covered: This review provides a biological background for TK inhibitors (TKIs) in AML and reviews their use in the clinic. TK expression and mutation in AML are explored with a focus on TKs associated with specific AML subsets and treatment outcomes. TKIs that specifically target FLT3, c-Kit, and Jak2 are discussed. TKI targeting of specific genes mutated in individual cases and general ‘untargeted’ use of these agents are highlighted. Lastly, the mechanisms TKI drug resistance in AML are explored. Expert Opinion: The use of TKIs in the clinic is improving outcomes for many patients. An improved understanding of tyrosine kinase biology and the expanding use of TKIs are likely to dramatically improve outcomes in the coming decade. TKIs and other targeted agents could gradually supplant the use of cytotoxic chemotherapy for AML.

AB - Introduction: Tyrosine kinases (TKs) drive cell survival and proliferation in many normal and malignant cell types. TKs are frequently mutated in acute myeloid leukemia (AML) and hence are increasingly targeted. The management of AML has dramatically improved because of TKI-targeted treatment. Areas Covered: This review provides a biological background for TK inhibitors (TKIs) in AML and reviews their use in the clinic. TK expression and mutation in AML are explored with a focus on TKs associated with specific AML subsets and treatment outcomes. TKIs that specifically target FLT3, c-Kit, and Jak2 are discussed. TKI targeting of specific genes mutated in individual cases and general ‘untargeted’ use of these agents are highlighted. Lastly, the mechanisms TKI drug resistance in AML are explored. Expert Opinion: The use of TKIs in the clinic is improving outcomes for many patients. An improved understanding of tyrosine kinase biology and the expanding use of TKIs are likely to dramatically improve outcomes in the coming decade. TKIs and other targeted agents could gradually supplant the use of cytotoxic chemotherapy for AML.

UR - http://www.scopus.com/inward/record.url?scp=85062360330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062360330&partnerID=8YFLogxK

U2 - 10.1080/13543784.2019.1584610

DO - 10.1080/13543784.2019.1584610

M3 - Review article

C2 - 30775933

AN - SCOPUS:85062360330

VL - 28

SP - 337

EP - 349

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 4

ER -